Clinical Trials ArenaOriginal article
Kyverna’s stiff-person syndrome trial shows one-year durability
Data Readoutpositivemiv-celPositive
AI Analysis
Summary
Kyverna's miv-cel demonstrated one-year durability in a stiff-person syndrome trial, potentially supporting its path toward first-to-market approval in an indication with no currently approved therapies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
one-year durability demonstrated in stiff-person syndrome trial
Importance:6/10
Sentiment:
0.70
stiff-person syndromecell therapyfirst-to-marketdurability dataunmet medical need
Read the original article
Published by Clinical Trials Arena on September 25, 2026 10:08 AM